Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)

Chronic active antibody-mediated rejection (caAMR) in kidney transplants is associated with irreversible tissue damage and a leading cause of graft loss in the long-term. However, the treatment for caAMR remai...

Source: Trials - March 22, 2024 Category: General Medicine Authors: Lillian Streichart, Marie Felldin, Jana Ekberg, Lars Mj örnstedt, Per Lindnér, Annette Lennerling, Verena Bröcker, Johan Mölne, Jan Holgersson, Kristien Daenen, Lars Wennberg, Tomas Lorant and Seema Baid-Agrawal Tags: Study protocol Source Type: research